Recent advances have led to development of targeted immune checkpoint inhibitors such as durvalumab, targeting programmed death ligand 1 (PD-L1), which has shown durable clinical benefit to patients with locally advanced NSCLC (2). Here, CD274 is linked to non-small cell lung carcinoma.